International comparisons of the management of patients with non-ST segment elevation acute myocardial infarction in the United Kingdom, Sweden, and the United States: The MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR registries  by McNamara, R.L. et al.
International Journal of Cardiology 175 (2014) 240–247
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdInternational comparisons of the management of patients with non-ST
segment elevation acute myocardial infarction in the United Kingdom,
Sweden, and the United States: The MINAP/NICOR, SWEDEHEART/
RIKS-HIA, and ACTION Registry-GWTG/NCDR registries☆,☆☆R.L. McNamara a,⁎, S.C. Chung b, T. Jernberg c, D. Holmes d, M. Roe d, A. Timmis e, S. James f, J. Deanﬁeld g,
G.C. Fonarow h, E.D. Peterson d, A. Jeppsson i, H. Hemingway b
a Yale University School of Medicine, Cardiovascular Medicine, New Haven, CT, USA
b Farr Institute of Health Informatics Research @ UCL Partners, University College London, London, UK
c Dept of Medicine (Huddinge), Cardiology, Karolinska Institutet, and Dept of Cardiology, Karolinska University Hospital, Stockholm, Sweden
d Duke Clinical Research Institution, Duke University Medical Center, Durham, NC, USA
e National Institute for Health Research, Biomedical Research Unit, Barts Health London, UK
f Dept. of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
g University College London, London, UK
h Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA
i Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenAbbreviations: ACEI, angiotensin converting enzyme i
Network Registry — Get With The Guidelines; ARB, angi
Coronary Events; MI, myocardial infarction; MINAP, Myoc
cardial infarction; NICOR, National Institute for Cardiovas
Swedish Heart Intensive Care Admissions; SWEDEHEART
Recommended Therapies; UK, England/Wales; US, United
☆ Each author takes responsibility for all aspects of the
☆☆ Funding acknowledgements: This study has been su
223153), National Institute for Health Research (Programm
Partners (MR/K006584/1) [HH, AT]. Barts and the London
Foundation [TJ, SJ], and the American College of Cardiolog
American College of Cardiology Foundation and the Am
Emergency Physicians, and the Society of Hospital Medic
of the NCDR or its associated professional societies identiﬁ
⁎ Corresponding author at: 333 Cedar Street, PO Box 2
E-mail address: robert.mcnamara@yale.edu (R.L. McN
http://dx.doi.org/10.1016/j.ijcard.2014.04.270
0167-5273/© 2014 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 29 January 2014
Accepted 30 April 2014
Available online 9 May 2014
Keywords:
Acute myocardial infarction
International comparisons
Clinical registries
Treatment
Objectives: To compare management of patients with acute non-ST segment elevation myocardial infarction
(NSTEMI) in three developed countries with national ongoing registries.
Background: Results from clinical trials suggest signiﬁcant variation in care across the world. However, interna-
tional comparisons in “real world” registries are limited.
Methods:We compared the use of in-hospital procedures and discharge medications for patients admitted with
NSTEMI from2007 to 2010 using the unselectiveMINAP/NICOR [England andWales (UK); n= 137,009], the un-
selective SWEDEHEART/RIKS-HIA (Sweden; n = 45,069), and the selective ACTION Registry-GWTG/NCDR
[United States (US); n = 147,438] clinical registries.
Results: Patients enrolled among the three registries were generally similar except those in the US who were
younger but had higher rates of smoking, diabetes, hypertension, prior heart failure, and prior MI than in
Sweden or in UK. Angiography and percutaneous coronary intervention (PCI) were performed more often in
the US (76% and 44%) and Sweden (65% and 42%) relative to the UK (32% and 22%). Discharge betablockers
were also prescribed more often in the US (89%) and Sweden (89%) than in the UK (76%). In contrast, discharge
statins, angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), and dualnhibitors; ACS, acute coronary syndrome; ACTION Registry-GWTG, The Acute Coronary Treatment and Intervention Outcomes
otensin receptor blockers; CABG, coronary artery bypass grafting; ECG, electrocardiogram; GRACE, Global Registry of Acute
ardial Ischemia National Audit Project; NCDR, National Cardiovascular Data Registry; NSTEMI, non-ST segment elevation myo-
cular Outcomes Research; PCI, percutaneous coronary intervention; RIKS-HIA, Register of Information and Knowledge About
, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to
States.
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241R.L. McNamara et al. / International Journal of Cardiology 175 (2014) 240–247antiplatelet agents (among those not receiving PCI) were higher in the UK (92%, 79%, and 71%) than in the US
(85%, 65%, 41%) and Sweden (81%, 69%, and 49%).
Conclusions: The care for patients with NSTEMI differed substantially among the three countries. These differ-
ences in care among countries provide an opportunity for future comparative effectiveness research as well as
identify opportunities for global quality improvement.© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).Table 1
Baseline characteristics.
Total NSTEMI⁎
UK† Sweden US‡
Number of patients 137,009 45,069 147,438
Number of participating hospitals 236 74 500
Demographics
Age, years, median (interquartile range) 73 (62–82) 73 (64–82) 67 (56–78)
Female sex, % 37.5 37.6 38.7
Risk factors
Current smoker, % 23 19.6 29.6
Diabetes, % 21.7 25.0 35.4
Hypertension, % 53.1 50.6 76.3
History of cardiovascular disease1. Introduction
International comparisons of care of community-based popula-
tions provide valuable opportunities for identifying areas for im-
provement in patient care. Many aspects of the management of
non-ST segment elevation myocardial infarction (NSTEMI) have a
strong evidence base. Clinical trials have shown improved outcomes
for an early invasive approach [1–3]; and antiplatelet therapy,
betablockers, statins, and angiotensin converting enzyme inhibitors
(ACEI) or angiotensin receptor blockers (ARB) upon discharge are
guideline recommendations [4–6] and evaluated by performance
measures [7]. Prior studies have demonstrated that the use of these
therapies in routine clinical practice in the United States (US) is sub-
optimal [8,9], especially in some subgroups [10–12], and with high
variability among hospitals [13,14].
Yet, there have been few international comparisons of care for
patients with NSTEMI. While populations from select sites within
clinical trials [15–17] or the Global Registry of Acute Coronary
Events (GRACE) [18] have been studied across various countries,
these are not representative of patients seen or care received in
routine community practice [19]. Larger registries with more pa-
tients per country are needed to make valid comparison among in-
dividual countries as well as enable the assessment of trends and
detailed subgroup analysis. In addition, more recent data are need-
ed to reﬂect the rapid change in clinical management of NSTEMI
patients.
We sought to compare patterns of in-hospital treatment and use
of interventional diagnostic and therapeutic procedures among pa-
tients admitted with NSTEMI from 2007 to 2010 across three nation-
al clinical registries. The Myocardial Ischemia National Audit Project
(MINAP)/National Institute for Cardiovascular Outcomes Research
(NICOR) [20] and the Swedish Web-system for Enhancement and
Development of Evidence-based care in Heart disease Evaluated Ac-
cording to Recommended Therapies (SWEDEHEART)/Register of In-
formation and Knowledge About Swedish Heart Intensive Care
Admissions (RIKS-HIA) [21] attempt to collect information on all pa-
tients with acute coronary syndrome (ACS), including NSTEMI, in all
hospitals providing ACS care in England/Wales (UK) and Sweden, re-
spectively. The Acute Coronary Treatment and Intervention Out-
comes Network Registry — Get With The Guidelines (ACTION
Registry-GWTG)/National Cardiovascular Data Registry (NCDR) in-
cludes patients with ACS in a large but self-selected group of hospi-
tals in the US [22].Heart failure, % 7.0 11.5 16.9
Myocardial infarction, % 22.8 27.8 28.8
Treatment prior to hospital admission
Single antiplatelet, % 30.4 42.2 39.4
Dual antiplatelet, % 4.3 4.4 13.4
Betablocker, % 28.8 44.4 44.2
ACEI§ or ARB(, % 38.3 37.3 42.5
Statin, % 44.8 32.3 43.5
PCI¶, % 7.5 12.3 25.0
CABG#, % 7.2 10.4 19.0
⁎ NSTEMI = non-ST segment elevation myocardial infarction.
† UK = United Kingdom (England and Wales).
‡ US = United States.
§ ACEI = Angiotensin converting enzyme inhibitor.
( ARB = Angiotensin receptor blocker.
¶ PCI = Percutaneous coronary intervention
# CABG = Coronary artery bypass grafting.2. Methods
2.1. Study population
The study population was drawn from all hospitals providing acute myocardial
infarction (MI) care in England and Wales (236 hospitals, 137,009 patients) and in
Sweden (74 hospitals, 45,069 patients) and a voluntary subset of hospitals, most
with capability to perform PCI, in the United States (500 hospitals, 147,438 patients).
Patients were eligible for our study if they were admitted between 1 January 2007
and 31 December 2010, and aged at least 30 years. For patients identiﬁed to have
multiple admissions we used the earliest record. NSTEMI diagnosis was based on
guidelines from European Society of Cardiology/American College of Cardiology/
American Heart Association. Speciﬁcally, elevated troponin levels were required.
The study complies with the Declaration of Helsinki and was approved by the
MINAP Academic Group, the Steering group of SWEDEHEART, and research and pub-
lications committee in ACTION.2.2. Patient characteristics and hospital treatment
Baseline variables of study interest include: demographic factors (age, gender), risk
factors (smoking, history of diabetes and hypertension), previous heart disease (heart
failure andMI), and medication and procedure use prior to hospital admission (antiplate-
let, betablocker, ACEI/ARB, or statin therapy and PCI, and prior coronary artery bypass
grafting (CABG)). Key hospital presentation variables included systolic blood pressure
and heart rate on arrival, ﬁrst hemoglobin and creatinine levels, and troponin levels;
hospital procedure variables included angiography and PCI, and dischargemedication var-
iables included antiplatelet therapy (aspirin, clopidogrel/prasugrel or both), betablockers,
ACEI/ARB, and statins. Regular chart review of randomly selected patients within each
hospital in SWEDEHEART/RIKS-HIA demonstrated a 96.1% agreement [21]. Re-entry of
data items of randomly selected patients in each hospital in MINAP/NICOR demonstrated
a median agreement of 89.5% [20]. Audit of records among randomly selected hospitals in
ACTION demonstrated an accuracy of 89.7% [23].2.3. Statistical methods
Numerical data are summarized asmedian and interquartile range (IQR) and categor-
ical data as frequency and percentage. The distribution of case-mix (demographics, past
history, and presentation characteristics) and treatment variables was compared in the
UK, Sweden and the US. To investigate the secular and age difference in acute manage-
ment of patients after NSTEMI, the analyses were stratiﬁed by admission year and age
groups (b60, 60–79, ≥80 years old). Recognizing the difference between nationwide
and voluntary registries, we conducted a sensitivity analysis, comparing the results of
NSTEMI patients attending PCI hospitals only. We deﬁned PCI hospitals as those hospitals
that performed aminimumof 24 PCI in the calendar year. Analyses were performed using
SAS version 9.0 or 9.2 (SAS Institute, Cary, North Carolina, U.S.A.) and IBM SPSS statistics
version 20.0 (IBM, Armonk, New York, U.S.A.).
Table 2
Presentation characteristics.
Total NSTEMI
UK Sweden US
Number of patients 137 009 45 069 147 438
Systolic blood pressure, mm Hg⁎,† 140 (121–160) 149 (130–168) 145 (125–166)
Heart rate, beat per minute⁎ 80 (68–96) 79 (66–94) 83 (70–99)
Hemoglobin, g/dl⁎,‡ 13.5 (12.0–14.8) 13.7 (12.5–14.8) 13.7 (12.2–14.9)
Creatinine, mmol/l⁎ 95 (79–119) 86 (72–107) 97.2 (79.6–123.8)
Troponin⁎,§ T, ng/ml( 0.33 (0.13–0.91) 0.39 (0.14–1.09) 0.1 (0.03–0.4)
I, ng/ml 1.9 (0.39–7.59) 2.0 (0.48–7.2) 0.4 (0.1–1.8)
Initial ECG or ECG determining treatment, % Transient ST segment elevation 2.7 4.0 2.7
ST segment depression 30.3 34.3 23.8
Other T wave abnormalities¶ 29.8 14.9 14.1
No ST segment abnormalities# 37.2 46.8 59.4
Abbreviations same as in Table 1 with the following additions:
⁎ Median (interquartile range) for all continuous variables.
† mmHg = millimeters of mercury.
‡ g/dl = grams per deciliter.
§ Troponin values in the UK and Sweden are a mix of initial and peak. Peak troponin values in the US were 0.6 (0.2, 1.7) and 4.7 (1.5, 14.3) for troponin T and I, respectively.
( ng/ml = nanograms per milliliter.
¶ Includes “T wave inversion” in RIKS-HIA and ACTION and “T wave changes only” in MINAP.
# Includes “Normal”, “None”, and “Other” categories.
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3.1. Patient demographic and clinical characteristics
The overall demographic and clinical characteristics for the patients
in the three registries showed many similarities, but some notable dif-
ferences were present (Table 1). The patients were youngest in the US
yet these individuals had higher rates of smoking, diabetes, hyperten-
sion, prior heart failure, and prior MI than those in Sweden or in UK.
Patients in Sweden presented to the hospital with a somewhat
higher blood pressure but lower creatinine level (Table 2). In the UK
and Sweden, troponin levels, which likely represent a mix of initial
and peak levels, were similar. Initial troponin levels were lower in the
US than the mix of initial and peak levels in the other two countries,
but peak levels were higher. Overall, electrocardiogram (ECG)Table 3
Treatment over time among NSTEMI patients, in all patients, by country, (%).
Admission year 2
In-hospital angiography MINAP (UK) 2
RIKS-HIA (Sweden) 6
ACTION (US) 7
In-hospital PCI MINAP (UK) 1
RIKS-HIA (Sweden) 3
ACTION (US) 4
Betablocker at discharge MINAP (UK) 7
RIKS-HIA (Sweden) 8
ACTION (US) 9
Antiplatelet at discharge Any MINAP (UK) 9
RIKS-HIA (Sweden) 9
ACTION (US) 9
Dual MINAP (UK) 7
RIKS-HIA (Sweden) 6
ACTION (US) 6
Statin at discharge MINAP (UK) 9
RIKS-HIA (Sweden) 7
ACTION (US) 8
ACEI or ARB at discharge MINAP (UK) 7
RIKS-HIA (Sweden) 6
ACTION (US) 6
N = 137,009 for MINAP (UK), 45,069 for RIKS-HIA (Sweden), and 147,438 for ACTION (US).
Abbreviations same as in Tables 1 and 2.abnormalities were comparable across the registries; of note, the UK
found more patients with T wave abnormalities and the US more
patients with non-ST segment abnormalities.3.2. Hospital treatment
Overall, angiographywas performedmore often in the US (76%) and
Sweden (65%) than in the UK (32%) (Table 3). Similarly, PCI was per-
formed more in the US (44%) and Sweden (42%) than in the UK (22%).
Prescription of dual antiplatelet therapywas similar across the coun-
tries in patients who received a PCI (Table 4). However, patients who
did not receive a PCI were discharged on dual antiplatelet therapy
more often in the UK (71%) than in Sweden (49%) and in the US (41%)
(Table 4). UK physicians prescribed betablockers at discharge least007 2008 2009 2010 2007–2010
2.9 27.9 35.5 38.8 31.8
0.4 62.7 66.8 69.8 64.8
2.4 75.2 76.6 78.3 76.0
6.5 20.0 23.4 26.1 21.8
9.0 40.2 42.7 45.9 41.9
1.8 43.3 44.2 45.5 43.9
3.1 74.9 76.5 78.7 76.0
8.8 88.6 88.2 89.0 88.6
0.1 89.4 89.1 89.1 89.4
4.2 94.0 94.7 95.4 94.6
3.6 94.4 95.0 94.9 94.5
5.0 95.1 95.6 95.7 95.4
4.9 74.6 76.4 78.6 76.2
3.2 66.9 70.6 72.4 68.1
4.7 65.1 66.9 68.0 66.4
1.2 91.0 91.5 92.1 91.5
9.7 81.4 82.7 83.6 81.1
2.0 83.7 85.4 85.9 84.5
7.1 77.5 79 80.6 78.7
5.5 68.3 69.9 72.1 68.8
5.9 64.5 64.3 63.9 64.5
Table 4
Treatment of NSTEMI patients, stratiﬁed by whether they received an in-hospital PCI, by country, (%).
Admission year Total PCI performed No PCI performed
Betablocker at discharge MINAP (UK) 76.0 85.7 72.8
RIKS-HIA (Sweden) 88.6 91.6 86.4
ACTION (US) 89.4 92.0 86.9
Antiplatelet at discharge Any MINAP (UK) 94.6 99.2 93.1
RIKS-HIA (Sweden) 94.5 99.5 90.7
ACTION (US) 95.4 99.5 91.7
Dual MINAP (UK) 76.2 93.2 70.6
RIKS-HIA (Sweden) 68.1 93.7 48.8
ACTION (US) 66.4 94.4 40.7
Statin at discharge MINAP (UK) 91.5 97.2 89.5
RIKS-HIA (Sweden) 81.1 94.9 71.9
ACTION (US) 84.5 91.1 78.5
ACEI or ARB at discharge MINAP (UK) 78.7 87.7 75.7
RIKS-HIA (Sweden) 68.8 75.2 64.0
ACTION (US) 64.5 70.4 59.1
N = 137,009 for MINAP (UK), 45,069 for RIKS-HIA (Sweden), and 147,438 for ACTION (US).
Abbreviations same as in Tables 1 and 2.
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patient received a PCI (Tables 3 and 4).3.3. Time trends
From 2007 to 2010, angiography and PCI increased in each country
(Table 3 and Fig. 1), most substantially in the UK. Betablocker, dual an-
tiplatelet, and ACEI/ARB use increased mildly in the UK. Prescription of
dual antiplatelet agents, statins, and ACE/ARB increased in Sweden.
The time trends showed a relatively stable use for each medication in
the US, except a slight increase in use of statins.3.4. Age groups
When stratiﬁed into three age groups – b 60 years, 60–79 years, and
≥80 years – the differences in PCI use were most marked in Sweden
(Fig. 2), with younger patients more often receiving PCI than older pa-
tients. Notably, PCI in patients b60 years and in 60–79 yearswas higher
in Sweden than in the US; however, PCI in patients ≥ 80 years was
lower in Sweden than in the US. Patterns of medication use in the age
subgroups were not consistent across medications (Appendix A).41.8
43.3 44.2
45.5
39.0 40.2
42.7
45.9
16.5
20.0
23.4
26.1
0
5
10
15
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25
30
35
40
45
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2007 2008 2009 2010
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UK
Fig. 1. In-hospital percutaneous coronary intervention (2007–2010). % — the percentage
of patients with NSTEMI who underwent percutaneous coronary intervention during
the hospitalization for each of the four years of the study for each registry.4. Discussion
In this comparison of ongoing national registries from the UK,
Sweden, and the US, we found that in-hospital management in terms
of interventional procedures for NSTEMI patients was more aggressive
in the US and Sweden than in the UK. However, this gap appears to be
narrowing over time. In addition, we found that, with the exception of
betablockers, secondary prevention medications were more commonly
prescribed in the UK at discharge than in Sweden or in the US. In partic-
ular, dual antiplatelet use in patients who did not undergo an in-
hospital PCI was highest in the UK.4.1. Validity of comparing national registries: case-mix
Understanding the case-mix of patients who are enrolled within
each of these national registries is critical for valid international com-
parisons of management. Overall, the baseline characteristics of the pa-
tients in the three registrieswere reasonably similar. The younger age of
the patients in theUSmay reﬂect the type of hospitals that participate in
the registry. The higher prevalence of smoking, hypertension, previous
heart failure and previous MI in the US may indicate different patient0
10
20
30
40
50
60
70
<60 years 60-79 years >=80 years
US
Sweden
UK
Fig. 2. Percutaneous coronary interventions in in-hospital, by age (2007–2010). % — the
percentage of patients with NSTEMI who underwent percutaneous coronary intervention
during the hospitalization over the four years of the study for each registry by age group,
60 years, 60–79 years, and ≥ 80 years.
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in the US. The increased prior use of medications and procedures
in the US and Sweden compared with the UK is deserving of further
study. The presentation characteristics (heart rate, systolic blood
pressure, hemoglobin, creatinine, troponin, and ECG abnormali-
ties) from each country suggest a reasonably similar infarction
severity.
4.2. Validity of comparing national registries
Importantly, we found that PCI use in all hospitals in Sweden by
2010matched that in the self-selected subset of hospitals in the US reg-
istry. Managementmay be different in those submitting to ACTION hos-
pitals than in thosewho do not. A comparison using only data from PCI-
capable hospitals in each country, eliminating some of the hospital-level
selection bias, showed similar results (Appendix B). In addition, the
ﬁnding of similarly high PCI rates in an unselected registry (Sweden)
and a selected registry (US) makes the differences seen in other aspects
of care more informative; it acts as a ‘positive control’. (If all aspects of
care differed in each country, selection bias would be more plausible.)
One explanation for the comparably high rates of PCI in Sweden is the
increased emphasis on system-wide quality improvement in that coun-
try [24,25]. Interestingly, the use of angiography was higher in the US
than in Sweden, but PCI rates were remarkably similar. This similarity
suggests that the use of PCI is not simply a function of fee-for-service
model in the US because the UK and Sweden have few ﬁnancial incen-
tives for clinicians. Further studies are needed to better explain these
practice patterns.
4.3. Procedures: trends, age
Between 2007 and 2010 the UK demonstrated a steeper increase in
in-hospital procedures consistent with concerted efforts to increase PCI
capability in the country [26].Whereas the overall use of PCIwas similar
in the US and Sweden, the use in age groups differed considerably.
Sweden showed the greatest impact of age on PCI use, with over 60%
of those less than 60 years receiving PCI, while less than 20% of those
greater than or equal to 80 years (Fig. 2). In contrast, in the US, those
less than 60 years received PCI only 56% of the time while those less
than or equal to 80 years 25%. One explanation for the high use in youn-
ger patients is that the concerted quality improvement efforts in
Sweden were aimed at those less than 80 years [27]. In addition, the ﬁ-
nancial incentive for PCI placement in the US, regardless of age, likely
has an impact.
4.4. Medications
We found markedly lower use of betablockers in the UK, both prior
to hospital admission and at discharge. The higher use of statins on dis-
charge in theUK, despite a lower use of betablockers, demonstrates a se-
lective practice pattern rather than an overall lowermedication use. The
explanation of this lower overall propensity for UK physicians to pre-
scribe betablockers is not clear but would appear to be unlikely due to
economic factors (betablockers being among the cheapest secondary
prevention medications) and unlikely to be due to lags in diffusion of
evidence implementation (betablockers being recommended in such
patients for longer than other secondary prevention medications). The
considerably lower use of ACEI/ARB on discharge, despite higher fre-
quency on admission, in Sweden and the US is interesting and deserves
further study. The relatively lowuse of dual antiplatelet therapy in those
patients who did not undergo PCI in both Sweden and the USmay iden-
tify an area for quality improvement.
Clinical trials have previously shown wide variation of practice
among countries or groups of countries in the management of
patients with myocardial infarction [15–17]. However, manage-
ment patterns within a clinical trial do not necessarily reﬂectmanagement in routine clinical practice [28]. Clinical registries ad-
dress some of the selection bias and are valuable resources for
comparison and for assessing trends in treatment [29–32]. In par-
ticular, for over six thousand patients from fourteen countries in
1999–2001, the Global Registry of Acute Coronary Events (GRACE)
found marked geographic differences for interventional therapy
after NSTEMI but only modest differences for oral pharmaceutical
secondary prevention therapies comparing groups of countries in
Europe, North and South America, and Australia [18]. Relevant to
our data, for July through December 2001, the use of PCI for patients
presenting with NSTEMI was 39.5% in the US, while 34.6% for those
in Europe. (It was 33.5% for those in Brazil/Argentina and 25.0% for
those in Australia.) However, the GRACE registry is not ongoing, did
not include a nationwide cohort of sites, nor attempt to recruit con-
secutive patients in all sites. The current study provides larger co-
horts of patients, including nearly all NSTEMIs in Sweden and the
UK. In addition, the current study reﬂects more recent practice pat-
terns. Of note, we compared the use of procedures and medications
in all patients, regardless of guideline indication or contraindica-
tion. For instance, we provide proportion of ACEI/ARB prescription
on discharge for all patients, not just those with left ventricular dys-
function. We aimed to highlight any practice variation, rather than
assess quality of care. Thus, the proportion of patients receiving
medication in our study is lower than reported use in eligible pa-
tients [8].
4.5. Limitations
While the data we present are the best available in the three
countries, they have important limitations. First, the US registry is
voluntary and consists of only a subset of hospitals in the US; the
registries from the UK and Sweden are mandated and represent
all hospitals that admit patients with AMI. Second, the processes
by which NSTEMI patients within hospitals are captured into the
registries may vary between countries and are not well under-
stood. In the UK, for example, MINAP has been shown to miss
some cases, and these missed cases have a higher mortality than
those included in the registry [33]. All three registries are designed
to include all patients admitted to the hospital. However, for each
of the registries, the number of patients with acute MI missed is dif-
ﬁcult to estimate and may differ across countries. Third, patient
historical elements such as history of cerebrovascular disease and
presentation elements such as left ventricular ejection fraction
would also be interesting but were not collected and recorded in
a standard fashion across all three registries. These data are depen-
dent on the quality of medical record documentation and abstrac-
tion, which may vary by registry. Finally, the comparisons are not
adjusted for patient case-mix. How the differences in patient char-
acteristics inﬂuenced management needs to be addressed in future
efforts.
4.6. Conclusion
Differences exist in the acute management of patients after NSTEMI
among the patients in national registries from the UK, Sweden, and the
US. Speciﬁcally, the use of invasive procedures such as angiography and
PCI and of betablockers on discharge was higher in the US and Sweden
than in the UK. Interestingly, these differences are decreasing over time.
Conversely, the use of somemedications, such as dual antiplatelet ther-
apy in patients who did not undergo PCI, was lower in the US and
Sweden. The impact of age on use of procedures and discharge medica-
tions appears highest in Sweden. Understanding the differences in pa-
tient characteristics and hospital management is critical preludes to
comparing outcomes and identifying areas for improvement in each
country.
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age groupsAppendix Table A1
Treatment over time among NSTEMI patients age b60 years (N = 27,901 in the UK; N = 47,467 in the US), by country, N (%).
Admission year 2007 2008 2009 2010 2007–10
Received in-hospital angiography MINAP (UK) 37.9 44.8 54.3 57.3 49.3
RIKS-HIA (Sweden) 88.5 91.7 93.7 94.7 92.0
ACTION (US) 86.2 88.9 90.0 91.0 89.3
Received in-hospital PCI MINAP (UK) 30.1 34.9 39.8 42.1 37.2
RIKS-HIA (Sweden) 61.6 63.0 64.1 66.2 63.7
ACTION (US) 53.8 55.8 56.1 57.1 55.9
Received dual antiplatelet at discharge MINAP (UK) 87.1 85.9 86.1 88.3 86.9
RIKS-HIA (Sweden) 80.5 81.4 84.8 84.3 82.7
ACTION (US) 73.7 73.6 75.2 75.6 74.7
Received single antiplatelet at discharge MINAP (UK) 10.1 11.2 10.9 9.6 10.4
RIKS-HIA (Sweden) 17.1 16.2 13.5 13.6 15.2
ACTION (US) 23.1 23.7 23.8 34.2 27.1
Received beta blocker at discharge MINAP (UK) 85.3 86.0 85.1 87.4 86.0
RIKS-HIA (Sweden) 90.7 91.0 90.4 90.4 90.6
ACTION (US) 90.7 90.6 90.0 90.0 90.8
Received ACEI or ARB at discharge MINAP (UK) 83.7 84.5 85.6 87,2 85.4
RIKS-HIA (Sweden) 63.7 65.4 66.9 71.2 66.7
ACTION (US) 66.5 65.3 66.1 65.8 65.9
Received statin at discharge MINAP (UK) 95.9 96.0 95.6 96.0 95.9
RIKS-HIA (Sweden) 92.7 93.6 94.1 94.5 93.7
ACTION (US) 87.2 88.1 89.8 89.9 89.0Appendix Table A2
Treatment over time among NSTEMI patients age 60–79 years (N = 65,621 in the UK; N = 66,968 in the US), by country, N (%).
Admission year 2007 2008 2009 2010 2007–10
Received in-hospital angiography MINAP (UK) 26.3 32.7 40.5 44.3 36.5
RIKS-HIA (Sweden) 74.0 78.0 81.9 83.1 79.1
ACTION (US) 77.4 80.1 82.2 82.8 81.0
Received in-hospital PCI MINAP (UK) 18.7 23.0 25.9 29.1 24.5
RIKS-HIA (Sweden) 46.1 48.6 51.2 53.8 49.9
ACTION (US) 42.8 43.5 45.2 45.9 44.6
Received dual antiplatelet at discharge MINAP (UK) 76.6 76.6 78.7 81.1 78.4
RIKS-HIA (Sweden) 66.6 70.7 73.7 75.3 71.5
ACTION (US) 65.0 65.1 66.9 68.3 66.7
Received single antiplatelet at discharge MINAP (UK) 17.9 17.9 16.6 15.1 16.8
RIKS-HIA (Sweden) 26.5 23.6 21.5 19.4 22.9
ACTION (US) 30.7 30.5 29.4 28.0 29.4
Received beta blocker at discharge MINAP (UK) 74.1 76.5 77.8 79.6 77.2
RIKS-HIA (Sweden) 88.4 89.0 88.9 89.3 88.9
ACTION (US) 91.0 89.9 89.5 89.7 90.0
Received ACEI or ARB at discharge MINAP (UK) 80.3 80.9 82.0 83.9 81.9
RIKS-HIA (Sweden) 68.5 71.7 74.7 76.3 72.7
ACTION (US) 67.5 66.5 66.2 65.6 66.3
Received statin at discharge MINAP (UK) 93.4 93.4 93.6 94.1 93.7
RIKS-HIA (Sweden) 87.0 89.1 90.1 90.3 89.1
ACTION (US) 83.7 85.4 87.0 87.3 86.1Appendix Table A3
Treatment over time among NSTEMI patients age ≥80 years (N = 43,487 in the UK; N = 33,
Admission year 20
Received in-hospital angiography MINAP (UK) 8
RIKS-HIA (Sweden) 23
ACTION (US) 43
Received in-hospital PCI MINAP (UK) 5
RIKS-HIA (Sweden) 15
ACTION (US) 23
Received dual antiplatelet at discharge MINAP (UK) 64
RIKS-HIA (Sweden) 41
ACTION (US) 51
Received single antiplatelet at discharge MINAP (UK) 27
RIKS-HIA (Sweden) 43
ACTION (US) 40
Received beta blocker at discharge MINAP (UK) 63003 in the UK), by country, N (%).
07 2008 2009 2010 2007–10
.1 10.3 15.3 17.7 13.1
.3 26.2 29.4 34.2 28.1
.6 46.2 36.2 49.4 46.7
.0 6.4 8.6 10.7 7.8
.4 16.9 18.5 22.0 18.1
.1 24.9 25.5 27.3 25.4
.3 64.6 66.2 68.3 65.9
.7 48.8 53.6 55.4 49.6
.1 51.9 54.3 55.5 53.5
.7 26.8 26.0 24.4 26.1
.1 37.6 34.3 32.8 37.1
.1 38.8 37.0 36.2 37.8
.7 65.6 68.9 71.4 67.6
Appendix Table A3 (continued)
Admission year 2007 2008 2009 2010 2007–10
RIKS-HIA (Sweden) 81.3 81.4 81.0 81.6 81.3
ACTION (US) 87.5 86.7 85.6 84.6 85.9
Received ACEI or ARB at discharge MINAP (UK) 68.1 68.1 70.0 70.9 69.3
RIKS-HIA (Sweden) 55.5 59.1 58.7 60.1 58.2
ACTION (US) 62.2 59.5 57.4 57.0 58.8
Received statin at discharge MINAP (UK) 84.8 84.1 85.3 86.2 85.1
RIKS-HIA (Sweden) 53.4 57.4 59.2 59.95 57.4
71.3 73.7 75.5 76.6 74.6
246 R.L. McNamara et al. / International Journal of Cardiology 175 (2014) 240–247ACTION (US)Appendix B. Treatment over time among NSTEMI patients admitted to hospitals with PCI capability (N = 88,674 in the UK; N = 26,531 in
Sweden; N = 135,718 in the US), by country, N (%)Admission year 2007 2008 2009 2010 2007–10
Received in-hospital angiography MINAP (UK) 32.7 37.2 44.5 48.1 41.5
RIKS-HIA (Sweden) 65.5 67.3 69.0 70.7 68.1
ACTION (US) 79.5 78.5 79.4 80.3 79.6
Received in-hospital PCI MINAP (UK) 24.8 27.6 30.5 33,5 29.6
RIKS-HIA (Sweden) 44.0 44.3 44.8 47.4 45.1
ACTION (US) 47.9 46.2 46.3 50.0 46.8
Received dual antiplatelet at discharge MINAP (UK) 76.1 74.7 77.9 80.7 77.6
RIKS-HIA (Sweden) 64.9 68.0 70.8 72.0 68.9
ACTION (US) 66.4 65.8 67.4 68.4 67.2
Received single antiplatelet at discharge MINAP (UK) 18.9 19.5 17.1 15.4 17.5
RIKS-HIA (Sweden) 29.7 27.4 24.5 23.0 26.1
ACTION (US) 29.4 29.6 28.4 27.4 28.5
Received beta blocker at discharge MINAP (UK) 74.5 75.3 77. 80.0 77.2
RIKS-HIA (Sweden) 89.5 90.0 88.9 89.5 89.5
ACTION (US) 90.6 89.6 89.3 89.1 89.6
Received ACEI or ARB at discharge MINAP (UK) 77.4 77.3 79.3 81.5 79.1
RIKS-HIA (Sweden) 67.3 69.5 70.9 73.2 70.2
ACTION (US) 66.2 64.8 64.5 64.0 64.7
Received statin at discharge MINAP (UK) 92.1 91.3 92.0 93.0 92.2
RIKS-HIA (Sweden) 81.5 83.2 83.6 83.6 83.0
ACTION (US) 83.2 84.2 85.8 86.1 85.1References
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